Wingo, a subsidiary of Meir Health (2327), initiates Phase 2a clinical trial for stroke treatment WG103
1. Enhanced Phase 2a trial design through collaboration with Beijing Tiantan Hospital
Wingo, a subsidiary of Meir Health (2327), is collaborating with Beijing Tiantan Hospital to initiate a Phase 2a clinical trial for its acute ischemic stroke (AIS) treatment, 'WG103.' This trial will involve 60 patients and compare a single high-dose administration (2.0×10^8 cells), three repeated low-dose administrations (1.0×10^8 cells), and a placebo control group. A randomized, double-blind design will be used to eliminate the placebo effect of stem cells and rigorously demonstrate their efficacy. This study, which began in August 2025, is expected to be completed by December 2028 and will demonstrate long-term biosafety.
2. Multi-target cell therapy mechanism overcoming the limitations of the golden hour
Acute ischemic stroke (AIS) is associated with a high rate of disability, but existing chemical therapies have a limited treatment window of 4.5 to 6 hours. In contrast, WG103, a human umbilical cord blood-derived mesenchymal stem cell (hUC-MSC)-based therapy, can be administered to patients up to 72 hours after symptom onset, making it highly versatile. This drug induces fundamental regeneration of brain tissue through a multi-target mechanism, including immunomodulation, neuroprotection, and angiogenesis. This can be an innovative solution that improves not only survival rates but also the quality of life for patients.
3. Explosive market size and addressing unmet medical needs in China
The global AIS treatment market is expected to reach approximately $10.38 billion by 2026, and the new drug segment is expected to grow to $2.63 billion by 2033. In China, where the aging population is rapidly increasing and the incidence of stroke is the highest, addressing the unmet needs of patients who have exceeded the golden hour is critical. Wingo is proactively gathering data in the region with the highest potential for commercial success through this large-scale clinical trial in China. If the trial is successful, it will overcome the spatiotemporal limitations of existing standard treatments and become a leader in the Asia-Pacific region.
4. Securing long-term indicators for regulatory approval in a global competitive landscape
Currently, the global stroke cell therapy market is dominated by companies such as Athersys with its MultiStem, but these companies are facing development difficulties. WG103 is the first stem cell clinical trial in Shenzhen, China, and is receiving significant attention from local regulatory authorities. This trial will monitor the modified Rankin Scale (mRS) and Barthel Index (BI) at 360 days as primary endpoints to demonstrate actual functional recovery. If Wingo succeeds in this, it will establish itself as a game-changer in the global regenerative medicine market, beyond the Asia-Pacific region.
This trial is a Phase 2a clinical trial for WG103, a stroke treatment developed by Wingo, a subsidiary of Meir Health (2327), and there are high commercial expectations as the global treatment market is expected to grow rapidly to $2.63 billion by 2033. In the short term, it is a good opportunity to fill the gap created by the delayed clinical trials of competitors such as Athersys and SanBio and narrow the development gap as a latecomer. In the medium to long term, it can secure a 72-hour treatment window, overcome the 4.5- to 6-hour limitation of existing thrombolytics (t-PA), and establish a basis for transforming the treatment paradigm. In addition, securing data through joint clinical trials with Beijing Tiantan Hospital will increase the possibility of technology transfer (L/O) to global pharmaceutical companies, which will have a positive impact on corporate value.
Source: ClinicalTrials.gov (api_ct)